Navigation Links
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Date:1/25/2008

ric acid (GABA), a dopamine-modulating neurotransmitter. The resulting excess GABA suppresses the increase in dopamine release caused by cocaine. All addictive drugs elevate dopamine levels in the parts of the brain associated with reward and reinforcement. It is thought that this reinforcing effect is the primary biochemical explanation for addiction. CPP-109 indirectly keeps dopamine levels in the normal range without impairing normal dopamine-based mechanisms. It is also thought that this effect may reduce craving, an effect in addicts which makes it very difficult for them to stop their drug habit.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries.

The Company's initial product candidate is CPP-109, also known as vigabatrin. CPP-109 has been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. CPP-109 was selected as one of the five most promising drugs entering Phase II trials in the July-September 2007 issue of The Ones To Watch, published by Thomson Scientific, a Thomson Corporation publication.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risk
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Cardium Therapeutics (NYSE Amex: ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Healing: Science and Industry Conference held December 10-13, ... The conference is attended by top industry leaders ... wound healing. Dr. Barbara K. Sosnowski, Cardium,s ...
(Date:12/14/2009)... SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we ... ) for some time now. Our largest hang up ... Although the Company,s fiscal June 2010 net income guidance ... fiscal 2009 reported net income of $7.9 million, the ... term EPS growth scenario, which depends upon the share ...
(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...
Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Time to Turn the Town Pink 57587 1Time to Turn the Town Pink 57587 2Dey L P Settles State of Utah Pricing Litigation 57583 1Dey L P Settles State of Utah Pricing Litigation 57583 2The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand 57580 1
... - ORENCIA is a First-in-Class Biologic Treatment Option Now Available ... Use in Pediatric Patients with ... Company (NYSE: BMY ) today announced that the U.S. ... signs,and symptoms in pediatric patients six years and older with ...
... Inc. (Nasdaq: ARNA ) announced today that ... of APD125 in patients with primary,insomnia. APD125 is ... the,potential to reduce insomnia symptoms and improve sleep ... APD125 is a double-blind, randomized, placebo-,controlled subjective study ...
Other Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 5
(Date:12/14/2009)... found simple activities like housework, gardening replaced tube watching ... was watching 25 or 26 hours of television a ... him to cut his tube time in half. , ... more calories each day, and not necessarily through strenuous ... Much of his newly freed time was spent reading ...
(Date:12/14/2009)... , ... La Jolla, Calif. (Vocus) -- The physicians at ... the new chief of staff of the 372-bed facility. Dr. Sedwitz ... Jan. 1, 2010. , , , , ,During his two-year term, ... Jolla’s administrative staff and its board of directors. Dr. Sedwitz will ...
(Date:12/14/2009)... Skilled nursing facilities (SNFs) in Ohio are ... to deal with a 92 percent increase in the ... to $12.01 per bed per day, scheduled for December ... will pay an additional $17,520 to the state each ... of $438,365 yearly. ,, Nearly 96 percent of skilled ...
(Date:12/14/2009)... of Tens of Thousands of New Chronic Hepatitis ... -- Legislation approved by Congress providing for federal ... helping to reduce tens of thousands of new ... United States, the National Viral Hepatitis Roundtable ... included in the FY 2010 Consolidated Appropriations bill ...
(Date:12/14/2009)... WASHINGTON, Dec. 14 The Hemophilia Federation ... ongoing labor issues involving the Teamsters Local 929 ... Jersey. The national blood system depends on skilled ... The blood is distilled into products such as ... von Willebrand disease. ,, The Division of ...
Breaking Medicine News(10 mins):Health News:Cutting TV Time Burns More Calories 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:HFA Voices Blood Safety Concerns 2
... Inc. today,announced the first true single port laparoscopic ... Medical Center, Springfield, MA, Dr. David Earle, Director,of ... a single 12mm access port in the umbilicus ... that does not rely on gaskets,or seals. This ...
... and Adults With ... Disabilities, ... results of its 27th annual ,Cones for Kids, Valentine,s Day,fundraiser to ... have raised just over $616,000 to help,children and adults with disabilities ...
... April 4, 2008 Eli Lilly and Company,(NYSE: ... Commission has approved a new,indication for FORSTEO(R) (teriparatide ... with sustained, systemic,glucocorticoid therapy in women and men ... initial positive opinion issued in February by,the Committee ...
... Recording Artist Chaka Khan, LOS ANGELES, April ... 1-millionth visitor to BODY WORLDS today. This marks,the ... run for BODY WORLDS,at the California Science Center ... Khan and a group of middle school,students from ...
... study finds aftereffects reverberate long after the incidents , , ... victims of male partner violence suffer a wide range ... Health Organization study that included 25,000 women in 11 ... from Bangladesh, Brazil, Ethiopia, Japan, Namibia, Peru, Samoa, Serbia ...
... is,pleased to join Harvard University,s Ash Institute for ... bi-annual conference,Frontiers of Innovation: 20 Years of Innovation ... On Monday evening, the executive,director of the Pan ... discussed multisector partnerships in tackling neglected,diseases and in ...
Other Medicine News:Health News:SurgiQuest Announces First Procedure Using AirSeal(TM) Access System 2Health News:Friendly's Dishes Out $616,000 for Easter Seals 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:California Science Center Welcomes 1-Millionth BODY WORLDS Visitor 2Health News:Male Partner Violence Hurts Women's Health Worldwide 2Health News:PAHEF Discusses Neglected Diseases and Disaster Preparedness with Innovative Leaders 2
...
...
...
Tip is bent towards port for downward irrigation. 25G x 7/8in (.50 x 16mm)...
Medicine Products: